Ibritumomab tiuxetan for non-Hodgkin's lymphoma

Research output: Contribution to journalArticle

Abstract

Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL). 90Y ibritumomab tiuxetan comprises the murine monoclonal antibody ibritumomab, the linker chelator tiuxetan and the radiolabeled isotope 90yttrium. 90Y ibritumomab tiuxetan has been demonstrated to be efficacious in the treatment of B-cell NHL. Initial Phase I/II trials established the therapeutic dose of ibritumomab tiuxetan for low-grade NHL to be 0.4 mCi/kg, or 0.3 mCi/kg for patients with mild thrombocytopenia. Currently, there are many ongoing trials of ibritumomab tiuxetan with different dose schedules and intensities, in combination with chemotherapy and with stem cell transplantation, in an attempt to improve response rate and duration and to study its effectiveness in other B-cell lymphomas, including diffuse large B-cell lymphoma and mantle cell lymphoma. Radioimmunotherapy has great promise and the safe incorporation of 90Y ibritumomab tiuxetan into treatment will hopefully result in improved survival for patients with NHL.

Original languageEnglish (US)
Pages (from-to)861-869
Number of pages9
JournalExpert Review of Anticancer Therapy
Volume6
Issue number6
DOIs
StatePublished - Jun 2006

Fingerprint

Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Radioimmunotherapy
Mantle-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Stem Cell Transplantation
Therapeutics
Chelating Agents
Combination Drug Therapy
Isotopes
Thrombocytopenia
Appointments and Schedules
Radiotherapy
Monoclonal Antibodies
ibritumomab tiuxetan
Survival

Keywords

  • CD20
  • Lymphoma
  • Radioimmunotherapy
  • Targeted irradiation
  • Zevalin®

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Ibritumomab tiuxetan for non-Hodgkin's lymphoma. / Johnston, Patrick Bruce; Bondly, Cara; Micallef, Ivana.

In: Expert Review of Anticancer Therapy, Vol. 6, No. 6, 06.2006, p. 861-869.

Research output: Contribution to journalArticle

@article{52530ee16a264b0f9dba57b22576af74,
title = "Ibritumomab tiuxetan for non-Hodgkin's lymphoma",
abstract = "Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL). 90Y ibritumomab tiuxetan comprises the murine monoclonal antibody ibritumomab, the linker chelator tiuxetan and the radiolabeled isotope 90yttrium. 90Y ibritumomab tiuxetan has been demonstrated to be efficacious in the treatment of B-cell NHL. Initial Phase I/II trials established the therapeutic dose of ibritumomab tiuxetan for low-grade NHL to be 0.4 mCi/kg, or 0.3 mCi/kg for patients with mild thrombocytopenia. Currently, there are many ongoing trials of ibritumomab tiuxetan with different dose schedules and intensities, in combination with chemotherapy and with stem cell transplantation, in an attempt to improve response rate and duration and to study its effectiveness in other B-cell lymphomas, including diffuse large B-cell lymphoma and mantle cell lymphoma. Radioimmunotherapy has great promise and the safe incorporation of 90Y ibritumomab tiuxetan into treatment will hopefully result in improved survival for patients with NHL.",
keywords = "CD20, Lymphoma, Radioimmunotherapy, Targeted irradiation, Zevalin{\circledR}",
author = "Johnston, {Patrick Bruce} and Cara Bondly and Ivana Micallef",
year = "2006",
month = "6",
doi = "10.1586/14787210.6.6.861",
language = "English (US)",
volume = "6",
pages = "861--869",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Ibritumomab tiuxetan for non-Hodgkin's lymphoma

AU - Johnston, Patrick Bruce

AU - Bondly, Cara

AU - Micallef, Ivana

PY - 2006/6

Y1 - 2006/6

N2 - Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL). 90Y ibritumomab tiuxetan comprises the murine monoclonal antibody ibritumomab, the linker chelator tiuxetan and the radiolabeled isotope 90yttrium. 90Y ibritumomab tiuxetan has been demonstrated to be efficacious in the treatment of B-cell NHL. Initial Phase I/II trials established the therapeutic dose of ibritumomab tiuxetan for low-grade NHL to be 0.4 mCi/kg, or 0.3 mCi/kg for patients with mild thrombocytopenia. Currently, there are many ongoing trials of ibritumomab tiuxetan with different dose schedules and intensities, in combination with chemotherapy and with stem cell transplantation, in an attempt to improve response rate and duration and to study its effectiveness in other B-cell lymphomas, including diffuse large B-cell lymphoma and mantle cell lymphoma. Radioimmunotherapy has great promise and the safe incorporation of 90Y ibritumomab tiuxetan into treatment will hopefully result in improved survival for patients with NHL.

AB - Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL). 90Y ibritumomab tiuxetan comprises the murine monoclonal antibody ibritumomab, the linker chelator tiuxetan and the radiolabeled isotope 90yttrium. 90Y ibritumomab tiuxetan has been demonstrated to be efficacious in the treatment of B-cell NHL. Initial Phase I/II trials established the therapeutic dose of ibritumomab tiuxetan for low-grade NHL to be 0.4 mCi/kg, or 0.3 mCi/kg for patients with mild thrombocytopenia. Currently, there are many ongoing trials of ibritumomab tiuxetan with different dose schedules and intensities, in combination with chemotherapy and with stem cell transplantation, in an attempt to improve response rate and duration and to study its effectiveness in other B-cell lymphomas, including diffuse large B-cell lymphoma and mantle cell lymphoma. Radioimmunotherapy has great promise and the safe incorporation of 90Y ibritumomab tiuxetan into treatment will hopefully result in improved survival for patients with NHL.

KW - CD20

KW - Lymphoma

KW - Radioimmunotherapy

KW - Targeted irradiation

KW - Zevalin®

UR - http://www.scopus.com/inward/record.url?scp=33745133748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745133748&partnerID=8YFLogxK

U2 - 10.1586/14787210.6.6.861

DO - 10.1586/14787210.6.6.861

M3 - Article

C2 - 16761929

VL - 6

SP - 861

EP - 869

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 6

ER -